Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring hypertension awareness in physicians: a cross-sectional study from Turkey.

Postepy w kardiologii interwencyjnej = Advances in interventional cardiology·2026
Same author

Optical coherence tomography-angiography findings of prediabetic patients.

Oman journal of ophthalmology·2024
Same author

Multiparametric assessment of right ventricular function in heart transplant recipients by echocardiography and relations with pulmonary hemodynamics.

Echocardiography (Mount Kisco, N.Y.)·2023
Same author

Answer Regarding: Potent P2Y12 Inhibitors and Bleeding Complications.

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir·2022
Same author

Evaluation of the relationship between para-aortic adipose tissue and ascending aortic diameter using a new method.

Acta cardiologica·2022
Same author

Effect of Post-Transplant Cardiac Angiographic Procedures on Post-Transplant Renal Function.

Transplantation proceedings·2022

Related Experiment Video

Updated: Jun 8, 2026

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Platelet function analysis with two different doses of aspirin.

Alp Aydinalp1, Ilyas Atar, Cihan Altin

  • 1Department of Cardiology, Medicine Faculty of Başkent University, Ankara, Turkey. aydinkalp@superonline.com

Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir
|October 12, 2010
PubMed
Summary

Higher aspirin doses (300 mg) improve platelet inhibition compared to lower doses (100 mg), particularly in women. This study highlights aspirin dose and female sex as key factors in achieving effective platelet inhibition.

More Related Videos

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Related Experiment Videos

Last Updated: Jun 8, 2026

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Area of Science:

  • Cardiology
  • Pharmacology
  • Hematology

Background:

  • Aspirin is a widely used antiplatelet medication.
  • Assessing the effectiveness of different aspirin dosages is crucial for optimizing patient outcomes.
  • Platelet function testing provides objective measures of antiplatelet therapy efficacy.

Purpose of the Study:

  • To compare platelet inhibition levels between patients receiving low-dose (100 mg) versus medium-dose (300 mg) aspirin.
  • To identify factors associated with incomplete platelet inhibition despite aspirin therapy.

Main Methods:

  • Prospective study of 159 cardiology outpatients on 100 mg or 300 mg daily aspirin.
  • Platelet reactivity assessed using the Platelet Function Analyzer (PFA)-100 system.
  • Incomplete platelet inhibition defined as normal collagen/epinephrine closure time (< 165 sec).

Main Results:

  • Overall, 22% of patients exhibited incomplete platelet inhibition.
  • Incomplete inhibition was significantly more prevalent in the 100 mg aspirin group (30.4%) compared to the 300 mg group (13.8%) (p=0.013).
  • Female sex and lower aspirin dose were independent predictors of incomplete platelet inhibition.

Conclusions:

  • Higher aspirin doses (300 mg) are associated with reduced incomplete platelet inhibition.
  • Female patients may be more susceptible to incomplete platelet inhibition.
  • Optimizing aspirin dosage may be particularly important for female patients to ensure adequate platelet inhibition.